Thank you Doc...that subgroup is, I understand, up to approximately 30% of the patient’s with GBM...that’s a lot of people. Certainly, one would think it would be approved for that subgroup. I just believe we have had such a horrible set-back in other therapies, that the research into DC must go on without another 10 year delay, and the FDA certainly should approve it for those it may help if in fact it is truly helping them. I guess I’m being naive.
Market Data 
Markets 
AI
